Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report

Descripción del Articulo

Vogt Koyanagi Harada syndrome (VKH) is a bilateral panuveitis included in the uveomeningeal syndromes. Treatment of its chronic stage is difficult because of poor response to mmunomodulation. Other therapeutic options include biological agents such as anti-TNF alpha. We present the case of a patient...

Descripción completa

Detalles Bibliográficos
Autores: Moya Ayre, Eugenio Franklin, Bermúdez Maldonado, Iván
Formato: artículo
Fecha de Publicación:2016
Institución:Universidad Nacional Mayor de San Marcos
Repositorio:Revistas - Universidad Nacional Mayor de San Marcos
Lenguaje:español
OAI Identifier:oai:ojs.csi.unmsm:article/11554
Enlace del recurso:https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/11554
Nivel de acceso:acceso abierto
Materia:Síndrome Uveomeningoencefalítico
Vogt Koyanagi Harada
Adalimumab
Infliximab.
Uveomeningoencephalitic syndrome
id REVUNMSM_c6c3d9b02caaf991be1e1f425f16bd76
oai_identifier_str oai:ojs.csi.unmsm:article/11554
network_acronym_str REVUNMSM
network_name_str Revistas - Universidad Nacional Mayor de San Marcos
repository_id_str
spelling Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case reportAdalimumab como alternativa terapéutica en el síndrome de Vogt Koyanagi Harada refractario al infliximab: reporte de casoMoya Ayre, Eugenio FranklinBermúdez Maldonado, IvánSíndrome UveomeningoencefalíticoVogt Koyanagi HaradaAdalimumabInfliximab.Uveomeningoencephalitic syndromeVogt Koyanagi HaradaAdalimumabInfliximab.Vogt Koyanagi Harada syndrome (VKH) is a bilateral panuveitis included in the uveomeningeal syndromes. Treatment of its chronic stage is difficult because of poor response to mmunomodulation. Other therapeutic options include biological agents such as anti-TNF alpha. We present the case of a patient with severe VKH resistant to infliximab that responded to adalimumab. Adalimumab is a humanized monoclonal antibody effective when there is resistance to infliximab in patients with chronic persistent VKH syndrome. The case presented is interesting because of uncommon resistance to this drug in the clinical practice; the use of tissue plasminogen activator contributed significantly to visual improvement.El síndrome de Vogt Koyanagi Harada (VKH) consiste en una panuveitis bilateral que forma parte de los síndromes uveomeníngeos. El tratamiento en estadio crónico es difícil por presentar pobre respuesta a la inmunomodulación, por lo que se recurre a opciones terapéuticas como agentes biológicos tipo anti-TNF alfa. Se describe el caso de una paciente con VKH severo y resistencia al infliximab, quien mostró respuesta al adalimumab. El adalimumab es un anticuerpo monoclonal humanizado efectivo en casos de resistencia al infliximab en pacientes con síndrome de VKH crónico persistente. El caso es de interés por ser infrecuente la resistencia a este medicamento en la práctica clínica, y el uso del activador de plasminógeno tisular contribuyó significativamente en la mejoría visual.Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana2016-03-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/1155410.15381/anales.v77i1.11554Anales de la Facultad de Medicina; Vol. 77 No. 1 (2016); 55-58Anales de la Facultad de Medicina; Vol. 77 Núm. 1 (2016); 55-581609-94191025-5583reponame:Revistas - Universidad Nacional Mayor de San Marcosinstname:Universidad Nacional Mayor de San Marcosinstacron:UNMSMspahttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/11554/10456Derechos de autor 2016 Eugenio Franklin Moya Ayre, Iván Bermúdez Maldonadohttps://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessoai:ojs.csi.unmsm:article/115542020-04-17T09:47:28Z
dc.title.none.fl_str_mv Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report
Adalimumab como alternativa terapéutica en el síndrome de Vogt Koyanagi Harada refractario al infliximab: reporte de caso
title Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report
spellingShingle Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report
Moya Ayre, Eugenio Franklin
Síndrome Uveomeningoencefalítico
Vogt Koyanagi Harada
Adalimumab
Infliximab.
Uveomeningoencephalitic syndrome
Vogt Koyanagi Harada
Adalimumab
Infliximab.
title_short Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report
title_full Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report
title_fullStr Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report
title_full_unstemmed Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report
title_sort Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report
dc.creator.none.fl_str_mv Moya Ayre, Eugenio Franklin
Bermúdez Maldonado, Iván
author Moya Ayre, Eugenio Franklin
author_facet Moya Ayre, Eugenio Franklin
Bermúdez Maldonado, Iván
author_role author
author2 Bermúdez Maldonado, Iván
author2_role author
dc.subject.none.fl_str_mv Síndrome Uveomeningoencefalítico
Vogt Koyanagi Harada
Adalimumab
Infliximab.
Uveomeningoencephalitic syndrome
Vogt Koyanagi Harada
Adalimumab
Infliximab.
topic Síndrome Uveomeningoencefalítico
Vogt Koyanagi Harada
Adalimumab
Infliximab.
Uveomeningoencephalitic syndrome
Vogt Koyanagi Harada
Adalimumab
Infliximab.
description Vogt Koyanagi Harada syndrome (VKH) is a bilateral panuveitis included in the uveomeningeal syndromes. Treatment of its chronic stage is difficult because of poor response to mmunomodulation. Other therapeutic options include biological agents such as anti-TNF alpha. We present the case of a patient with severe VKH resistant to infliximab that responded to adalimumab. Adalimumab is a humanized monoclonal antibody effective when there is resistance to infliximab in patients with chronic persistent VKH syndrome. The case presented is interesting because of uncommon resistance to this drug in the clinical practice; the use of tissue plasminogen activator contributed significantly to visual improvement.
publishDate 2016
dc.date.none.fl_str_mv 2016-03-14
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/11554
10.15381/anales.v77i1.11554
url https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/11554
identifier_str_mv 10.15381/anales.v77i1.11554
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/11554/10456
dc.rights.none.fl_str_mv Derechos de autor 2016 Eugenio Franklin Moya Ayre, Iván Bermúdez Maldonado
https://creativecommons.org/licenses/by-nc-sa/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2016 Eugenio Franklin Moya Ayre, Iván Bermúdez Maldonado
https://creativecommons.org/licenses/by-nc-sa/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
dc.source.none.fl_str_mv Anales de la Facultad de Medicina; Vol. 77 No. 1 (2016); 55-58
Anales de la Facultad de Medicina; Vol. 77 Núm. 1 (2016); 55-58
1609-9419
1025-5583
reponame:Revistas - Universidad Nacional Mayor de San Marcos
instname:Universidad Nacional Mayor de San Marcos
instacron:UNMSM
instname_str Universidad Nacional Mayor de San Marcos
instacron_str UNMSM
institution UNMSM
reponame_str Revistas - Universidad Nacional Mayor de San Marcos
collection Revistas - Universidad Nacional Mayor de San Marcos
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1795238255317221376
score 13.949927
Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case report
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares